The interactions between the effects of the sympathetic nervous system (SNS) and angiotensin II (ANG II) on vascular extracellular matrix (ECM) synthesis were determined in rats.
The mRNA and protein content of collagen I, collagen III and elastin in the abdominal aorta (AA) and femoral artery (FA) was investigated in Wistar–Kyoto rats treated for 5 weeks with guanethidine, a sympathoplegic, losartan, an ANG II AT1 receptor (AT1R) blocker, or both. The effects of noradrenaline (NE) and ANG II on collagen III and elastin mRNA, and the receptor involved, were tested in cultured vascular smooth muscle cells (VSMCs) in vitro.
Guanethidine increased collagen types I and III and decreased elastin, while losartan had an opposite effect, although without effect on collagen III. The combination of treatments abrogated changes induced by simple treatment with collagen I and elastin, but increased collagen III mRNA in AA and not in FA. NE stimulated collagen III mRNA via β receptors and elastin via α1 and α2 receptors. ANG II stimulated collagen III but inhibited elastin mRNA via AT1R.
Overall, SNS and ANG II exert opposite and antagonistic effects on major components of ECM in the vascular wall. This may be of relevance for the choice of a therapeutic strategy in vascular diseases.
HumphreyJD. Vascular adaptation and mechanical homeostasis at tissue, cellular, and sub-cellular levels. Cell Biochem Biophys2008; 50: 53–78.
2.
VellemanSGMcCormickRJElyDJarroldBBPattersonRAScottCB. Collagen characteristics and organization during the progression of cholesterol-induced atherosclerosis in Japanese quail. Exp Biol Med (Maywood)2001; 226: 328–333.
3.
Brouwers-CeilerDLNelissen-VranckenHJSmitsJFDe MeyJG. The influence of angiotensin II-induced increase in aortic wall mass on compliance in rats in vivo. Cardiovasc Res1997; 33: 478–484.
4.
O’RourkeJJiangXHaoZConeREHandAR. Distribution of sympathetic tissue plasminogen activator (tPA) to a distant microvasculature. J Neurosci Res2005; 79: 727–733.
5.
MinerECMillerWL. A look between the cardiomyocytes: the extracellular matrix in heart failure. Mayo Clin Proc2006; 81: 71–76.
6.
OsadchiiOEWoodiwissAJDeftereosDNortonGR. Temporal changes in myocardial adrenergic regulation with the progression to pump dysfunction after chronic beta-adrenoreceptor activation in rats. Pflugers Arch2007; 455: 251–260.
7.
FronekKBloorCMAmielDChvapilM. Effect of long-term sympathectomy on the arterial wall in rabbits and rats. Exp Mol Pathol1978; 28: 279–289.
8.
LacolleyPGlaserEChallandePBoutouyriePMignotJPDuriezM. Structural changes and in situ aortic pressure-diameter relationship in long-term chemical-sympathectomized rats. Am J Physiol1995; 269: H407–416.
9.
BalakrishnanSMWangHDGopalakrishnanVWilsonTWMcNeillJR. Effect of an endothelin antagonist on hemodynamic responses to angiotensin II. Hypertension1996; 28: 806–809.
10.
d’UscioLVShawSBartonMLüscherTF. Losartan but not verapamil inhibits angiotensin II-induced tissue endothelin-1 increase: role of blood pressure and endothelial function. Hypertension1998; 31: 1305–1310.
11.
FyhrquistFMetsärinneKTikkanenI. Role of angiotensin II in blood pressure regulation and in the pathophysiology of cardiovascular disorders. J Hum Hypertens1995; 9Suppl 5: S19–24.
12.
ZuckerIHWangWPliquettRULiuJLPatelKP. The regulation of sympathetic outflow in heart failure. The roles of angiotensin II, nitric oxide, and exercise training. Ann N Y Acad Sci2001; 940: 431–443.
13.
DabHHachaniRHodrojWSaklyMBriccaGKacemK. Differential control of collagen synthesis by the sympathetic and renin-angiotensin systems in the rat left ventricle. Auton Neurosci2009; 151: 106–110.
14.
CoxSLBenAStoryDFZiogasJ. Evidence for the involvement of different receptor subtypes in the pre- and postjunctional actions of angiotensin II at rat sympathetic neuroeffector sites. Br J Pharmacol1995; 114: 1057–1063.
15.
DendorferARaaschWTempelKDominiakP. Interactions between the renin-angiotensin system (RAS) and the sympathetic system. Basic Res Cardiol1998; 93: 24–29.
16.
BaltJCMathyMJNapAPfaffendorfMvan ZwietenPA. Effect of the AT1-receptor antagonists losartan, irbesartan, and telmisartan on angiotensin II-induced facilitation of sympathetic neurotransmission in the rat mesenteric artery. J Cardiovasc Pharmacol2001; 38: 141–148.
17.
RaaschWDominiakPZieglerADendorferA. Reduction of vascular noradrenaline sensitivity by AT1 antagonists depends on functional sympathetic innervation. Hypertension2004; 44: 346–351.
18.
HilgersKFVeelkenRRupprechtGReehPWLuftFCMannJF. Angiotensin II facilitates sympathetic transmission in rat hind limb circulation. Hypertension1993; 21: 322–328.
19.
WangMZhangJSpinettiGJiangLQMonticoneRZhaoD. Angiotensin II activates matrix metalloproteinase type II and mimics age-associated carotid arterial remodeling in young rats. Am J Pathol2005; 167: 1429–1442.
20.
CeruttiCKurdiMBriccaGHodrojWPaultreCRandonJ. Transcriptional alterations in the left ventricle of three hypertensive rat models. Physiol Genomics2006; 27: 295–308.
21.
RoglerGLacknerKJSchmitzG. Effects of fluvastatin on growth of porcine and human vascular smooth muscle cells in vitro. Am J Cardiol1995; 76: 114A–116A.
22.
HodrojWLegedzLFoudiNCeruttiCBourdillonMCFeugierP. Increased insulin-stimulated expression of arterial angiotensinogen and angiotensin type 1 receptor in patients with type 2 diabetes mellitus and atheroma. Arterioscler Thromb Vasc Biol2007; 27: 525–531.
SupowitSCEthridgeRTZhaoHKatkiKADipetteDJ. Calcitonin gene-related peptide and substance P contribute to reduced blood pressure in sympathectomized rats. Am J Physiol Heart Circ Physiol2005; 289: H1169–H1175.
25.
MehtaPKGriendlingKK. Angiotensin II cell signaling: physiological and pathological effects in the cardiovascular system. Am J Physiol Cell Physiol2007; 292: C82–97.
26.
NakajimaMHutchinsonHFujinagaMHayashidaWMorishitaRZhangL. The angiotensin II type 2 (AT2) receptor antagonizes the growth effects of the AT1 receptor: gain-of-function study using gene transfer. Proc Natl Acad Sci U S A1995; 92: 10,663–10,667.
27.
YamadaHHoriuchiMAkishitaMDzauVJ. Regulation of vascular development and differentiation by angiotensin II type 2 receptor. Hypertension1997; 30: 470.
28.
ShanmugamSCorvolPGascJ-M. Angiotensin II type 2 receptor mRNA expression in the developing cardiopulmonary system of the rat. Hypertension1996; 28: 91–97.
29.
HoriuchiMAkishitaMDzauVJ. Recent progress in angiotensin II type 2 receptor research in the cardiovascular system. Hypertension1999; 33: 613–621.
30.
TimmermansPBSmithRD. The diversified pharmacology of angiotensin II-receptor blockade. Blood Press Suppl1996; 2: 53–61.
31.
OpieLH. The neuroendocrinology of congestive heart failure. Cardiovasc J S Afr2002; 13: 171–178.
32.
Arteaga-SolisEGayraudBRamirezF. Elastic and collagenous networks in vascular diseases. Cell Struct Funct2000; 25: 69–72.
33.
LurieKGBristowMRMinobeWAMasekMBillinghamME. 6-Hydroxydopamine mediated cardiotoxicity in rabbits. Am J Cardiovasc Pathol1988; 2: 181–191.
34.
FacoettiAFallariniSMiserereSBertolottiAFerreroITozziR. Histochemical study of cardiac mast cells degranulation and collagen deposition: interaction with the cathecolaminergic system in the rat. Eur J Histochem2006; 50: 133–140.
35.
O’CallaghanCJWilliamsB. The regulation of human vascular smooth muscle extracellular matrix protein production by alpha- and beta-adrenoceptor stimulation. J Hypertens2002; 20: 287–294.
36.
HeathJWBurnstockG. Selectivity of neuronal degeneration produced by chronic guanethidine treatment. J Neurocytol1977; 4: 397–405.
37.
KatoHSuzukiHTajimaSOgataYTominagaTSatoA. Angiotensin II stimulates collagen synthesis in cultured vascular smooth muscle cells. J Hypertens1991; 9: 17–22.
38.
IzzoJLJr. Systolic hypertension, arterial stiffness, and vascular damage: role of the renin–angiotensin system. Blood Press Monit2000; 5(Suppl 2): S7–S11.
WeberKTBrillaCGCampbellSEZhouGMatsubaraLGuardaE. Pathologic hypertrophy with fibrosis: the structural basis for myocardial failure. Blood Press1992; 1: 75–85.
43.
BrillaCGRuppHFunckRMaischB. The renin-angiotensin-aldosterone system and myocardial collagen matrix remodelling in congestive heart failure. Eur Heart J1995; 16Suppl O: 107–109.
44.
KuschnirE. The left ventricle and hemodynamic patterns in essential hypertension. Regul Pept2005; 128: 221–225.
45.
NagaseHBrewK. Designing TIMP (tissue inhibitor of metalloproteinases) variants that are selective metalloproteinase inhibitors. Biochem Soc Symp2003; 70: 201–212.
46.
DabHHachaniRHodrojWSaklyMBriccaGKacemK. Differential control of MMP and t-PA/PAI-1 expressions by sympathetic and renin-angiotensin systems in rat left ventricle. Auton Neurosci2009; 150: 27–32.
47.
FordCMLiSPickeringJG. Angiotensin II stimulates collagen synthesis in human vascular smooth muscle cells. Involvement of the AT(1) receptor, transforming growth factor-beta, and tyrosine phosphorylation. Arterioscler Thromb Vasc Biol1999; 19: 1843–1851.
48.
AdiguzelEAhmadPJFrancoCBendeckMP. Collagens in the progression and complications of atherosclerosis. Vasc Med2009; 14: 73–89.
49.
KizerJRDahlöfBKjeldsenSEJuliusSBeeversGde FaireU. Stroke reduction in hypertensive adults with cardiac hypertrophy randomized to losartan versus atenolol: the Losartan Intervention For Endpoint reduction in hypertension study. Hypertension2005; 45: 46–52.
